| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Astragaloside III targets multiple pathways. It increases NKG2D and induces TACE phosphorylation. It induces apoptosis. It has antiviral activity against dengue serotypes 1 and 3. It has anticancer activity against breast and colon cancer. Its antioxidant activity makes it a research tool for investigating mechanisms in cardiovascular and cerebrovascular disease models.
|
|---|---|
| ln Vitro |
In vitro, Astragaloside III can effectively reduce cancer cell survival. It shows antiviral activity against dengue serotype 1 and serotype 3 at 3.125-6.25 μg/mL. It induces apoptosis. It has anti-gastric ulcer effects and exhibits strong growth-promoting effects in cultured GES-1 cells. Quantitative IC50 values for its cytotoxic effects against specific cancer cell lines are not detailed in the publicly available sources.
|
| ln Vivo |
In vivo, Astragaloside III can inhibit tumor growth. The potential mechanism is the induction of cell apoptosis signaling pathways, suggesting that it provides a new therapeutic tool to treat breast cancer. It has cardioprotective effects and causes improvement in cognitive function. It can be used in the prevention of cardio-cerebral vascular diseases. It also is an antioxidant.
|
| Enzyme Assay |
For cell-free assays, the antioxidant activity of Astragaloside III can be measured using DPPH or ABTS radical scavenging assays. Its antiviral activity against dengue virus can be assessed using viral protease inhibition assays. Its ability to induce apoptosis can be studied by measuring caspase activity using fluorogenic substrates (e.g., DEVD-AFC for caspase-3). Its effect on NKG2D and TACE phosphorylation can be assessed using kinase activity assays with purified enzymes.
|
| Cell Assay |
For in vitro cellular assays, the anticancer activity of Astragaloside III is assessed in cancer cell lines such as breast and colon cancer cells. Cells are treated with various concentrations of the compound, and cell viability is measured using MTT or SRB assays. Apoptosis is assessed by flow cytometry (Annexin V/PI staining) and caspase activity assays. Its antiviral activity is assessed in dengue virus-infected cell lines by measuring viral replication via plaque assay or qPCR.
|
| Animal Protocol |
For in vivo studies, Astragaloside III could be administered orally or intraperitoneally in mouse xenograft models of breast or colon cancer. Tumor volume is measured periodically. In models of cardiovascular disease, endpoints include assessment of cardiac function and histopathology. Its neuroprotective effects can be evaluated in models of cognitive impairment using behavioral tests and brain tissue analysis.
|
| ADME/Pharmacokinetics |
Astragaloside III (CAS 84687-42-3) has a molecular formula of C41H68O14 and a molecular weight of 784.97 g/mol. It is also known as Astrasieversianin IV and Cyclosieversioside B. Purity is typically >98% for research use. Solubility: soluble in DMSO and other organic solvents. For in vitro studies, stock solutions are prepared in DMSO. Storage: powder at -20°C for up to 3 years; in solvent at -80°C for 6 months.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is publicly available. As a natural saponin from Astragalus membranaceus, it is generally considered to have low toxicity, but standard toxicological studies would be required for drug development. In vitro cytotoxicity assays in various cell lines are typically performed alongside efficacy studies to confirm that observed effects are not due to a general reduction in cell viability.
|
| References | |
| Additional Infomation |
Astragaloside III is a triterpenoid saponin, a derivative of cycloastragalol, with a 2-O-β-D-glucopyranosyl-β-D-xylanosyl moiety linked at position 3 via a glycosidic bond. It is both a triterpenoid saponin and a disaccharide derivative. Its function is related to cycloastragalol. Astragaloside III has been reported to be found in Astragalus hoantchy, Astragalus lepsensis, and other organisms with relevant data. See also: Root (part) of the closely related Astragalus propinquus.
Astragaloside III is a research-grade compound and is not approved for therapeutic use. It serves primarily as a pharmacological tool for studying cardioprotection, neuroprotection, and antiviral mechanisms. Its mechanism of action involves induction of apoptosis, antiviral activity, and antioxidant effects. It is a natural product from Astragalus membranaceus. No clinical trials have been reported. |
| Molecular Formula |
C41H68O14
|
|---|---|
| Molecular Weight |
784.9702
|
| Exact Mass |
784.46
|
| CAS # |
84687-42-3
|
| PubChem CID |
441905
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
906.8±65.0 °C at 760 mmHg
|
| Flash Point |
502.2±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.621
|
| LogP |
1.4
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
55
|
| Complexity |
1460
|
| Defined Atom Stereocenter Count |
21
|
| SMILES |
C[C@]12CC[C@@]34C[C@@]35CC[C@@H](C([C@@H]5[C@H](C[C@H]4[C@@]1(C[C@@H]([C@@H]2[C@]6(CC[C@H](O6)C(C)(C)O)C)O)C)O)(C)C)O[C@H]7[C@@H]([C@H]([C@@H](CO7)O)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O
|
| InChi Key |
FVFSMBDVZVUETN-BQAOMNQWSA-N
|
| InChi Code |
InChI=1S/C41H68O14/c1-35(2)24(53-34-30(26(46)21(45)17-51-34)54-33-29(49)28(48)27(47)22(16-42)52-33)9-11-41-18-40(41)13-12-37(5)32(39(7)10-8-25(55-39)36(3,4)50)20(44)15-38(37,6)23(40)14-19(43)31(35)41/h19-34,42-50H,8-18H2,1-7H3/t19-,20-,21+,22+,23-,24-,25-,26-,27+,28-,29+,30+,31-,32-,33-,34-,37+,38-,39+,40-,41+/m0/s1
|
| Chemical Name |
(2S,3R,4S,5S,6R)-2-[(2S,3R,4S,5R)-2-[[(1S,3R,6S,8R,9S,11S,12S,14S,15R,16R)-9,14-dihydroxy-15-[(2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethyl-6-pentacyclo[9.7.0.01,3.03,8.012,16]octadecanyl]oxy]-4,5-dihydroxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~63.70 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.18 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (3.18 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.18 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2739 mL | 6.3697 mL | 12.7393 mL | |
| 5 mM | 0.2548 mL | 1.2739 mL | 2.5479 mL | |
| 10 mM | 0.1274 mL | 0.6370 mL | 1.2739 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
